Stephen Friend MD PhD

Dr. Friend is the President of Sage Bionetworks and a Director of Sage Bionetworks EU. Dr Friend is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community.  He has more than a decade of experience using large datasets and integrating system biology approaches to complex diseases. Dr. Friend has been a senior advisor to the NCI and several biotech companies, a Trustee of the AACR and was recently was made a AAAS Fellow. Following a BA in Philosophy, an MD PhD, and training in pediatric oncology, he teamed with Nobel laureate Lee Hartwell to create an innovative gene research cooperative called the “Seattle Project” that led to the formation of Rosetta Inpharmatics which was subsequently sold to Merck for over $600m and where he became Senior Vice President. Recognizing that genetic datasets were too fragmented and siloed and data and model sharing was inadequate, he left Merck in 2009 to form Sage Bionetworks. Dr. Friend is also an Ashoka Fellow and the co-leader of the Arch2POCM initiative that is building an open, pre-competitive research infrastructure for collaborative pre-clinical and proof of concept in man drug development.


Jean Charles Soria MD PhD

Jean-Charles Soria is a Professor of Medecine and Medical Oncology at South-Paris University. He is a tenure-track and full time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA. Professor Soria is currently head of the phase I program at Institut Gustave Roussy and is a member of the lung cancer unit with a focus on targeted therapies. His main research interest are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer. He is also involved in translational research aspects related to tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO executive committee from 2008 to 2009, and serves as an ASCO committee member since 2006. He has contributed to over 230  peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology.